[1]
|
Vollmers, H.P. and Brändlein, S. (2009) Natural antibodies and cancer. New Biotechnology, 25, 294-298.
doi:10.1016/j.nbt.2009.03.016
|
[2]
|
Collins, C., Tsui, F.W. and Shulman, M.J. (2002) Differential activation of human and guinea pig complement by pentameric and hexameric IgM. European Journal of Immunology, 32, 1802-1810.
doi:10.1002/1521-4141(200206)32:6<1802::AID-IMMU1802>3.0.CO;2-C
|
[3]
|
Wiersma, E.J., Collins, C., Fazel, S. and Shulman, M.J. (1998) Structural and functional analysis of J chain-deficient IgM. The Journal of Immunology, 160, 5979-5989.
|
[4]
|
Irie, R.F., Ollila, D.W., O’Day, S. and Morton, D.L. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 53, 110- 117. doi:10.1007/s00262-003-0436-1
|
[5]
|
Jones, P.C., Sze, L.L., Liu, P.Y., Morton, D.L. and Irie, R.F. (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. Journal of the National Cancer Institute, 66, 249-254.
|
[6]
|
Ollert, M.W., David, K., Schmitt, C., Hauenschild, A., Bredehorst, R., Erttmann, R., et al. (1996) Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 4498-4503. doi:10.1073/pnas.93.9.4498
|
[7]
|
Vollmers, H.P., O’Connor, R., Müller, J., Kirchner, T. and Müller-Hermelink, H.K. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Research, 49, 2471-2476.
|
[8]
|
Casali, P. and Schettino, E.W. (1996) Structure and function of natural antibodies. Current Topics in Microbiology and Immunology, 210, 167-179.
doi:10.1007/978-3-642-85226-8_17
|
[9]
|
Horn, M.P., Zuercher, A.W., Imboden, M.A., Rudolf, M.P., Lazar, H., Wu, H., et al. (2010) Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrobial Agents and Chemotherapy, 54, 2338-2344. doi:10.1128/AAC.01142-09
|
[10]
|
Ilag, L.L. (2011) Immunoglobulin M as a vaccine adjuvant. Medical Hypotheses, 77, 473-478.
doi:10.1016/j.mehy.2011.06.013
|
[11]
|
Yang, Q.E. (2009) IgM, not IgG, a key for HIV vaccine. Vaccine, 27, 1287-1288.
doi:10.1016/j.vaccine.2008.12.030
|
[12]
|
Frutiger, S., Hughes, G.J., Paquet, N., Lüthy, R. and Jaton, J.C. (1992) Disulfide bond assignment in human J chain and its covalent pairing with immunoglobulin M. Biochemistry, 31, 12643-12647. doi:10.1021/bi00165a014
|
[13]
|
Niles, M.J., Matsuuchi, L. and Koshland, M.E. (1995) Polymer IgM assembly and secretion in lymphoid and nonlymphoid cell lines: Evidence that J chain is required for pentamer IgM synthesis. Proceedings of the National Academy of Sciences of the United States of America, 92, 2884-2888. doi:10.1073/pnas.92.7.2884
|
[14]
|
Brewer, J.W., Randall, T.D., Parkhouse, R.M. and Corley, R.B. (1994) Mechanism and subcellular localization of secretory IgM polymer assembly. The Journal of Biological Chemistry, 269, 17338-17348.
|
[15]
|
Racine, R. and Winslow, G.M. (2009) IgM in microbial infections: Taken for granted? Immunology Letters, 125, 79-85. doi:10.1016/j.imlet.2009.06.003
|
[16]
|
Metzger, H. (1970) Structure and function of gamma M macroglobulins. Advances in Immunology, 12, 57-116.
doi:10.1016/S0065-2776(08)60168-6
|
[17]
|
Randall, T.D., King, L.B. and Corley, R.B. (1990) The biological effects of IgM hexamer formation. European Journal of Immunology, 20, 1971-1979.
doi:10.1002/eji.1830200915
|
[18]
|
Brewer, J.W., Randall, T.D., Parkhouse, R.M. and Corley, R.B. (1994) IgM hexamers? Immunology Today, 15, 165- 168. doi:10.1016/0167-5699(94)90313-1
|
[19]
|
Hughey, C.T., Brewer, J.W., Colosia, A.D., Rosse, W.F. and Corley, R.B. (1998) Production of IgM hexamers by normal and autoimmune B cells: Implications for the physiologic role of hexameric IgM. The Journal of Immunology, 161, 4091-4097.
|
[20]
|
Reddy, P.S. and Corley, R.B. (1999) The contribution of ER quality control to the biologic functions of secretory IgM. Immunology Today, 20, 582-588.
doi:10.1016/S0167-5699(99)01542-X
|
[21]
|
Johansen, F.E., Braathen, R. and Brandtzaeg, P. (2000) Role of J chain in secretory immunoglobulin formation. Scandinavian Journal of Immunology, 52, 240-248.
doi:10.1046/j.1365-3083.2000.00790.x
|
[22]
|
Butler, M. and Meneses-Acosta, A. (2012) Recent advances in technology supporting biopharmaceutical production from mammalian cells. Applied Microbiology and Biotechnology, 96, 885-894.
doi:10.1007/s00253-012-4451-z
|
[23]
|
Kim, J.Y., Kim, Y.G. and Lee, G.M. (2012) CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Applied Microbiology and Biotechnology, 93, 917-930.
doi:10.1007/s00253-011-3758-5
|
[24]
|
De Jesus, M. and Wurm, F.M. (2011) Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. European Journal of Pharmaceutics and Biopharmaceutics, 78, 184-188.
doi:10.1016/j.ejpb.2011.01.005
|
[25]
|
Kunert, R., Wolbank, S., Stiegler, G., Weik, R. and Katinger, H. (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Research and Human Retroviruses, 20, 755-762. doi:10.1089/0889222041524571
|
[26]
|
Gilmour, J.E., Pittman, S., Nesbitt, R. and Scott, M.L. (2008) Effect of the presence or absence of J chain on expression of recombinant anti-Kell immunoglobulin M. Transfusion Medicine and Hemotherapy, 18, 167-174.
doi:10.1111/j.1365-3148.2008.00853.x
|
[27]
|
Tchoudakova, A., Hensel, F., Murillo, A., Eng, B., Foley, M., Smith, L., et al. (2009) High level expression of functional human IgMs in human PER.C6 cells. MAbs, 1, 163-171.
|
[28]
|
Kuczewski, M., Schirmer, E., Lain, B. and Zarbis-Papastoitsis, G. (2011) A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnology Journal, 6, 56-65.
doi:10.1002/biot.201000292
|
[29]
|
Havenga, M.J., Holterman, L., Melis, I., Smits, S., Kaspers, J., Heemskerk, E., et al. (2008) Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity. Biotechnology and Bioengineering, 100, 273-283.
doi:10.1002/bit.21757
|
[30]
|
Wolbank, S., Kunert, R., Stiegler, G. and Katinger, H. (2003) Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. Journal of Virology, 77, 4095-4103.
doi:10.1128/JVI.77.7.4095-4103.2003
|
[31]
|
Azuma, Y., Ishikawa, Y., Kawai, S., Tsunenari, T., Tsunoda, H., Igawa, T., et al. (2007) Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma. Clinical Cancer Research, 13, 2745-2750.
doi:10.1158/1078-0432.CCR-06-2919
|
[32]
|
Tarköy, M., Wyss, M. and Rudolf, M.P. (2010) A comparative characterization of dipentameric (IgM)(2) and pentameric IgM species present in preparations of a monoclonal IgM for therapeutic use. Journal of Pharmaceutical and Biomedical Analysis, 51, 1084-1090.
doi:10.1016/j.jpba.2009.11.003
|
[33]
|
Harris, R.J., Shire, S.J. and Winter, C. (2004) Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Development Research, 61, 137-154.
doi:10.1002/ddr.10344
|
[34]
|
Vorauer-Uhl, K., Wallner, J., Lhota, G., Katinger, H. and Kunert, R. (2010) IgM characterization directly performed in crude culture supernatants by a new simple electrophoretic method. Journal of Immunological Methods, 359, 21-27.
|
[35]
|
Steindl, F., Jungbauer, A., Wenisch, E., Himmler, G. and Katinger, H. (1987) Isoelectric precipitation and gel chromatography for purification of monoclonal IgM. Enzyme and Microbial Technology, 9, 361-364.
|
[36]
|
Gagnon, P., Hensel, F. and Richieri, R. (2007) Recent advances in the purification of IgM monoclonal antibodies. 3rd Wilbio Conference on Purification of Biological Products, Waltham, 24-26 September 2007.
http://www.validated.com/revalbio/pdffiles/PUR07a.pdf
|
[37]
|
Gagnon, P. (2009) Monoclonal antibody purification with hydroxyapatite. New Biotechnology, 25, 287-293.
|
[38]
|
Tscheliessnig, A., Ong, D., Lee, J., Pan, S., Satianegara, G., Schriebl, K., et al. (2009) Engineering of a two-step purification strategy for a panel of monoclonal immunoglobulin M directed against undifferentiated human embryonic stem cells. Journal of Chromatography A, 1216, 7851-7864.
|
[39]
|
Gagnon, P., Hensel, F., Lee, S. and Zaidi, S. (2011) Chromatographic behavior of IgM: DNA complexes. Journal of Chromatography A, 1218, 2405-2412.
|
[40]
|
Lee, J., Gan, H.T., Latiff, S.M.A., Chuah, C., Lee, W.Y., Yang, Y.-S., et al. (2012) Principles and applications of steric exclusion chromatography. Journal of Chromatography A, 1270, 162-170.
|
[41]
|
Hanala, S. (2012) The new ParaDIgm: IgM from bench to clinic: November 15-16, 2011, Frankfurt, Germany. Multi- Agent-Based Simulation (MABS), 4, 555-561.
|